Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

MGI Tech Sells Complete Genomics to Swiss Rockets for $50M – Divests US Unit to Mitigate Geopolitical Risks

Fineline Cube Feb 25, 2026
Company Deals

Junshi Biosciences Partners with Antengene on Cancer Combination – JS207 PD‑1/VEGF Bispecific Plus ATG‑037 CD73 Inhibitor

Fineline Cube Feb 25, 2026
Company Deals

Dartsbio Licenses PACAP Antibody DS009 to Slate Medicines – $130M Series A Fuels Global Migraine Development

Fineline Cube Feb 25, 2026
Company Deals

Henlius Licenses Serplulimab to Abbott for Emerging Markets – Expands Anti‑PD‑1 Global Footprint

Fineline Cube Feb 25, 2026
Company Deals Digital

Insilico Medicine Partners with MSKCC to Discover Gastroesophageal Cancer Targets – AI‑Driven Multi‑Omics Analysis

Fineline Cube Feb 25, 2026
Policy / Regulatory

FDA Issues Draft Guidance on Plausible Mechanism Framework – Accelerates Approval Pathway for Individualized Genetic Therapies

Fineline Cube Feb 24, 2026
Company Drug

Novo Nordisk to Cut Semaglutide List Prices by 35‑50% – Wegovy, Ozempic, Rybelsus Standardized at $675/Month

Fineline Cube Feb 25, 2026
Company Drug

SinoMab’s First‑in‑Class IL‑25R Antibody SM17 Wins NMPA IND Approval – Novel IBD Therapy Enters Clinic

Fineline Cube Feb 25, 2026
Company

BeiGene Launches Charitable Access Program for Brukinsa in Low-Income Countries

Fineline Cube Mar 14, 2024

BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), the China-based biotech firm, has announced that...

Company

Innovent Biologics Denies Lab Closure, Confirms Relocation to California

Fineline Cube Mar 14, 2024

Innovent Biologics (HKG: 1801) has refuted unconfirmed reports regarding the closure of its Rockville, Maryland...

Company Deals

Novartis Acquires IFM Due for $90 Million, Expanding STING-Inhibitor Pipeline

Fineline Cube Mar 14, 2024

Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has announced the acquisition of IFM Due, a...

Company Legal / IP Policy / Regulatory

BIO Reverses Support for WuXi AppTec Amid Security Concerns, Plans Legislative Shift

Fineline Cube Mar 14, 2024

The Biotech Innovation Organization (BIO), a US-based industry lobbying group, has reversed its stance on...

Company Drug

European Commission Approves Pfizer’s Prevenar 20 for Pediatric Use

Fineline Cube Mar 14, 2024

The European Commission (EC) has granted regulatory approval to Pfizer (NYSE: PFE) for its 20-valent...

Company Drug

Merck Plans Broader HPV Vaccine Development, Targeting African and Asian Populations

Fineline Cube Mar 14, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has unveiled plans to develop a multi-valent human...

Company Deals

Shanghai BDgene Partners with SPH RD to Advance Gene Therapy Development

Fineline Cube Mar 14, 2024

Shanghai BDgene Technology Co., Ltd., a China-based specialist in gene therapy, has entered into a...

Company Drug

Allist Pharmaceuticals Secures NMPA Approval for Phase I Study of AST2169 Liposome in KRAS G12D Tumors

Fineline Cube Mar 14, 2024

Shanghai-based biotech Allist Pharmaceuticals Co., Ltd. (SHA: 688578) has received clearance from the National Medical...

Company Deals

BioGeometry and Sanyou Biopharmaceuticals Forge AI Partnership for Antibody Drug Discovery

Fineline Cube Mar 14, 2024

BioGeometry, an AI-driven pharmaceutical company based in Beijing, has formed a strategic partnership with Sanyou...

Company Drug

Sichuan Biokin Gains NMPA Approval for Phase I Study of BL-M05D1 in Advanced Solid Tumors

Fineline Cube Mar 14, 2024

Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) has received approval from the National Medical Products...

Company Drug

Genor Biopharma Secures NMPA Review for Lerociclib in Advanced Breast Cancer Indication

Fineline Cube Mar 14, 2024

Genor Biopharma Co., Ltd. (HKG: 6998) has announced that the National Medical Products Administration (NMPA)...

Company Deals

Fosun Pharma Launches RMB 5 Billion Fund to Boost Biopharmaceutical Investments in Shenzhen

Fineline Cube Mar 14, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) has unveiled plans to establish...

Policy / Regulatory

Shanghai Unveils 17 Measures to Enhance Medical Administration Business Environment

Fineline Cube Mar 14, 2024

Shanghai’s Medical Product Administration has unveiled a comprehensive set of 17 measures aimed at fostering...

Company Drug

Pfizer’s Adcetris Combo Shows Improved Survival in Relapsed/Refractory DLBCL Late-Stage Trial

Fineline Cube Mar 13, 2024

Pfizer (NYSE: PFE) has announced positive results from a late-stage clinical trial for its antibody-drug...

Company Deals

MSD Strikes Deal with Pearl Bio to Tap into Synthetic Biology for Oncology Targets

Fineline Cube Mar 13, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has entered into a strategic agreement with Pearl...

Company Deals

MSD Partners with IDEAYA Biosciences to Develop Combination Therapy for Endometrial Cancer

Fineline Cube Mar 13, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a partnership with IDEAYA Biosciences (NASDAQ:...

Company

Innovent Biologics Allegedly Closes US Research Facility, Shifts Focus to China

Fineline Cube Mar 13, 2024

Innovent Biologics (HKG: 1801), a China-based biotech firm, has reportedly closed down a research team...

Company Deals

VectorBuilder Partners with Minaris Regenerative Medicine to Enhance Gene Therapy Solutions

Fineline Cube Mar 13, 2024

VectorBuilder, a specialist in genetic engineering based in China, has entered into a strategic partnership...

Company Drug

Bio-Thera Solutions Gets Green Light for Phase Ib/II Study of ADC BAT8008 in Advanced Solid Tumors

Fineline Cube Mar 13, 2024

Guangzhou-based Bio-Thera Solutions (SHA: 688177) has announced that it has received approval from the National...

Company Drug

Betta Pharmaceuticals’ Ensartinib Accepted for FDA Review for First-Line ALK+ NSCLC Treatment

Fineline Cube Mar 13, 2024

Betta Pharmaceuticals (SHE: 300558), a pharmaceutical company based in China, has announced that the market...

Posts pagination

1 … 350 351 352 … 626

Recent updates

  • MGI Tech Sells Complete Genomics to Swiss Rockets for $50M – Divests US Unit to Mitigate Geopolitical Risks
  • Junshi Biosciences Partners with Antengene on Cancer Combination – JS207 PD‑1/VEGF Bispecific Plus ATG‑037 CD73 Inhibitor
  • AbbVie Invests $380M in Illinois API Manufacturing – AI‑Enabled Facilities for Neuroscience and Obesity Drugs
  • Novo Nordisk to Cut Semaglutide List Prices by 35‑50% – Wegovy, Ozempic, Rybelsus Standardized at $675/Month
  • Dartsbio Licenses PACAP Antibody DS009 to Slate Medicines – $130M Series A Fuels Global Migraine Development
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

MGI Tech Sells Complete Genomics to Swiss Rockets for $50M – Divests US Unit to Mitigate Geopolitical Risks

Company Deals

Junshi Biosciences Partners with Antengene on Cancer Combination – JS207 PD‑1/VEGF Bispecific Plus ATG‑037 CD73 Inhibitor

Company

AbbVie Invests $380M in Illinois API Manufacturing – AI‑Enabled Facilities for Neuroscience and Obesity Drugs

Company Drug

Novo Nordisk to Cut Semaglutide List Prices by 35‑50% – Wegovy, Ozempic, Rybelsus Standardized at $675/Month

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.